跳至主要内容
临床试验/ISRCTN57549638
ISRCTN57549638进行中(未招募)未知

Prevention of bleeding in haemophilia A by prophylactic treatment with Octanate®, Wilate®, Nuwiq®: a prospective, multi-national, non-interventional study to evaluate routine practice prophylactic treatment schedules – NIS-Previq

Octapharma GmbH0 个研究点目标入组 200 人开始时间: 2015年3月23日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 19/03/2024:
  • 1. Haemophilia A
  • 2. Treated with Octanate®, Wilate®or Nuwiq®
  • 3. Prophylactic treatment schedule for at least 6 months is to be expected
  • 4. Good compliance regarding documentation of FVIII treatments and bleeding episodes (in case home treatment is performed)
  • Previous inclusion criteria:
  • 1. Haemophilia A
  • 2. Treated with Nuwiq
  • 3. Prophylactic treatment schedule for at least 6 months is to be expected
  • 4. Good compliance regarding documentation of FVIII treatments and bleeding episodes (in case home treatment is performed)

排除标准

  • Patients with known contraindications as specified in the SPC

研究者

相似试验

Prevention of bleeding in haemophilia A by... | 临床试验